Boston Scientific Corp (BSX)vsBioventus Inc (BVS)
BSX
Boston Scientific Corp
$48.55
-0.55%
HEALTHCARE · Cap: $70.87B
BVS
Bioventus Inc
$9.04
+3.91%
HEALTHCARE · Cap: $589.41M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 3477% more annual revenue ($20.61B vs $576.30M). BSX leads profitability with a 17.3% profit margin vs 4.9%. BSX appears more attractively valued with a PEG of 0.58. BSX earns a higher WallStSmart Score of 76/100 (B+).
BSX
Strong Buy76
out of 100
Grade: B+
BVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.4%
Fair Value
$37.35
Current Price
$48.55
$11.20 premium
Intrinsic value data unavailable for BVS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
No standout strengths identified
Areas to Watch
No major concerns identified
0.0% earnings growth
Smaller company, higher risk/reward
4.9% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : BVS
PEG of 1.12 suggests the stock is reasonably priced for its growth.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Bear Case : BVS
The primary concerns for BVS are EPS Growth, Market Cap, Profit Margin. Thin 4.9% margins leave little buffer for downturns.
Key Dynamics to Monitor
BSX profiles as a mature stock while BVS is a value play — different risk/reward profiles.
BVS carries more volatility with a beta of 0.67 — expect wider price swings.
BSX is growing revenue faster at 11.6% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (76/100 vs 51/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Bioventus Inc
HEALTHCARE · MEDICAL DEVICES · USA
Bioventus Inc., a medical device company, focuses on developing and commercializing clinical treatments that involve and enhance the body's natural healing process in the United States and internationally. The company is headquartered in Durham, North Carolina.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?